Navigation Links
VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
Date:11/19/2009

SAN DIEGO, Nov. 19 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions. The VerifyNow P2Y12 Test is used to measure the antiplatelet effect of medications, such as clopidogrel (Plavix®), that reduce platelet reactivity by blocking the platelet P2Y12 receptor.

The POPular study is the first head-to-head comparison of multiple platelet function tests in predicting adverse events in patients undergoing elective coronary stenting. The study investigators mentioned that many of the tests for platelet reactivity evaluated in the study are either labor-intensive, have significant time constraints, or cannot be performed at the point-of-care. The investigators noted that the VerifyNow System does not have these limitations. The investigators also speculated that recent data may soon make platelet reactivity testing a routine clinical tool.

"We are at a time when much attention has been drawn to antiplatelet medications, such as Plavix, and understanding the variability in patients' response to these medications. For example, patients who use certain heartburn medications or patients with a specific genetic disposition may not receive the desired platelet inhibiting effect of Plavix. These are only two of the many factors that may contribute to the variability in response to these life-saving medications. The VerifyNow P2Y12 Test can assist physicians by providing a direct measure of the antiplatelet effect in each patient so they can make more informed treatment decisions," said Timothy Still, president and CEO of Accumetrics.

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including aspirin, P2Y12 inhibitors [e.g. prasugrel (Effient(TM)) and clopidogrel (Plavix)], and GP IIb/IIIa inhibitors [e.g. abciximab (ReoPro®) and eptifibatide (Integrilin®)], the VerifyNow System provides a valuable tool to help physicians make more informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly and Company.

    CONTACT:
    Megan Rusnack
    Lippert/Heilshorn & Associates
    212-838-3777
    mrusnack@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    858-404-8260
    press@accumetrics.com

SOURCE Accumetrics, Inc.


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
5. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
6. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
7. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
8. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
9. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
10. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):